Skip to Content

My Chem/Biochem



Johnson CW, Haigis KM. All Roads Lead to Rome: YAP/TAZ Activity Influences Efficacy of KRASG12C Inhibitors. Cancer Res. 2023 Dec 15;83(24):4005-4007. doi: 10.1158/0008-5472.CAN-23-3547. PMID: 38098448. 
Johnson CW, Fetics SK, Davis KP, Rodrigues JA, Mattos C. Allosteric site variants affect GTP hydrolysis on Ras. Protein Sci. 2023 Aug 24:e4767. doi: 10.1002/pro.4767. Epub ahead of print. PMID: 37615343. 
Yang MH, Tran TH, Hunt B, Agnor R, Johnson CW, Shui B, Waybright TJ, Nowak JA, Stephen AG, Simanshu DK, Haigis KM. Allosteric regulation of switch-II domain controls KRAS oncogenicity. Cancer Res. 2023 Aug 9:CAN-22-3210. doi: 10.1158/0008-5472.CAN-22-3210. Epub ahead of print. PMID: 37556505. 


Johnson CW*, Burkhart DL*, Haigis KM, Classification of K-RAS activating mutations and the implications for therapeutic intervention. Cancer Discov. 2022 Apr 1;12(4):913-923. doi: 10.1158/2159-8290.CD-22-0035. PMID: 35373279; PMCID: PMC8988514. 
Johnson CW, Seo H-S, Terrell EM, Yang M-H, KleinJan F, Gebregiworgis T, Gasmi-Seabrook GMC, Geffken EA, Lakhani J, Song K, Bashyal P, Popow O, Paulo JA, Liu A, Mattos C, Marshall CB, Ikura M, Morrison DK, Dhe-Paganon S, Haigis KM, Regulation of GTPase function by autophosphorylation. Mol Cell. 2022 Mar 3;82(5):950-968.e14. doi: 10.1016/j.molcel.2022.02.011. Epub 2022 Feb 23. PMID: 35202574; PMCID: PMC8986090.


Johnson CW*, Lin YJ*, Reid D, Parker J, Pavlopoulos S, Dischinger P, Graveel C, Aguirre AJ, Steensma M, Haigis KM, Mattos C. Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D. Cell Rep. 2019 Aug 6;28(6):1538-1550.e7. doi: 10.1016/j.celrep.2019.07.026. PMID: 31390567; PMCID: PMC6709685. 
Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM. Tissue-Specific Oncogenic Activity of KRASA146T. Cancer Discov. 2019 Jun;9(6):738-755. doi: 10.1158/2159-8290.CD-18-1220. Epub 2019 Apr 5. PMID: 30952657; PMCID: PMC6548671.


Johnson CW*, Reid D*, Parker JA, Salter S, Knihtila R, Kuzmic P, Mattos C. The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects. J Biol Chem. 2017 Aug 4;292(31):12981-12993. doi: 10.1074/jbc.M117.778886. Epub 2017 Jun 19. PMID: 28630043; PMCID: PMC5546037. (Selected for reprint in a special virtual issue: Cancer: 


Ting PY, Johnson CW, Fang C, Cao X, Graeber TG, Mattos C, Colicelli J. Tyrosine phosphorylation of RAS by ABL allosterically enhances effector binding. FASEB J. 2015 Sep;29(9):3750-61. Doi: 10.1096/fj.15-271510. Epub 2015 May 21. PMID: 25999467; PMCID: PMC4550377. 
Johnson CW, Buhrman G, Ting PY, Colicelli J, Mattos C. Expression, purification, crystallization and X-ray data collection for RAS and its mutants. Data Brief. 2015 Dec 17;6:423-7. Doi: 10.1016/j.dib.2015.12.007. PMID: 26866052; PMCID: PMC4710794. 


Kearney BM, Johnson CW, Roberts DM, Swartz P, Mattos C. DRoP: a water analysis program identifies Ras-GTP-specific pathway of communication between membrane-interacting regions and the active site. J Mol Biol. 2014 Feb 6;426(3):611-29. doi: 10.1016/j.jmb.2013.10.036. Epub 2013 Nov 2. PMID: 24189050. 


Johnson CW, Mattos C. The allosteric switch and conformational states in Ras GTPase affected by small molecules. Enzymes. 2013;33 Pt A:41-67. doi: 10.1016/B978-0-12-416749-0.00003-8. Epub 2013 Aug 8. PMID: 25033800.

Challenge the conventional. Create the exceptional. No Limits.